A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Craig Selzman, MD
- Phone Number: (801) 581-5311
- Email: craig.selzman@hsc.utah.edu
Study Contact Backup
- Name: Joseph Tonna, MD
- Phone Number: (801) 581-5311
- Email: joseph.tonna@hsc.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Age ≥18
- 2. Hospitalized and symptomatic (cough, fevers, SOB, or sputum production)
- 3. SARS CoV-2 laboratory positive obtained within 14 days of enrollment
Exclusion Criteria:
- 1. None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment
Treatment groups: 1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL) |
Administration of amniotic fluid in SARS-CoV-2 positive patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ventilator Free Days
Time Frame: Measured from hospital admission day 60 after admission.
|
Days alive and off mechanical ventilation at day 60.
Measured only among patients who receive invasive mechanical ventilation.
|
Measured from hospital admission day 60 after admission.
|
|
Duration of supplemental oxygen use
Time Frame: Measured from hospital admission to day 60.
|
Duration from hospital admission until cessation of supplemental oxygen use.
Measured only among patients who do not receive invasive mechanical ventilation.
|
Measured from hospital admission to day 60.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All cause mortality
Time Frame: Measured at day 60 or at hospital discharge, whichever comes first.
|
Survival at day 60 or hospital discharge
|
Measured at day 60 or at hospital discharge, whichever comes first.
|
|
Systemic inflammation
Time Frame: Measured at day 5 post enrollment.
|
Systemic inflammation at 5 days measured by serum IL-6.
|
Measured at day 5 post enrollment.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Craig Selzman, MD, University of Utah
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 131618
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.